Anti-Human ApoE4 (Clone 4E4) – Purified No Carrier Protein

Synthetic peptide made to an internal region of human ApoE4

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This purified antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only (RUO). Non-Therapeutic.

2-8°C Wet Ice

4E4 activity is specific to ApoE4, recognizing an internal domain present exclusively in the ApoE4 isoform.

ApoE is produced differentially in the central nervous system by astrocytes and microglia as well as peripherally by the liver and macrophages. ApoE does not cross the blood–brain barrier.

Apolipoprotein E (ApoE) is a glycoprotein involved in lipid metabolism encoded by three isoforms, ApoE2, ApoE3, and ApoE4, which differ at residues 112 and 158 (E2: C112, C158; E3: C112, R158; E4: R112, R158)¹. Carriers of the ApoE4 isoform are more likely to develop Alzheimer’s Disease (AD), with cognitive changes also occurring earlier². ApoE4 has been implicated in increased amyloid β deposition, a key marker of AD, and has an effect on lipid metabolism, inflammation, phosphorylation of tau protein, and mitochondrial function. ApoE4 is also a risk factor for cerebral amyloid angiopathy, dementia with Lewy bodies, tauopathy, cerebrovascular disease, multiple sclerosis, vascular dementia, and is related to poor outcome following head injury. In contrast, ApoE4 is protective for age-related macular degeneration. Lower concentrations of ApoE are found in ApoE4 carriers. However, it is unknown how the amount of ApoE4 present intersects with its functional activity to increase risk of disease. Anti-ApoE4 therapies that aim to mitigate the pathological effects of ApoE4 and inhibit amyloid accumulation are under study.

1. Veiga S, Rodríguez-Martín A, Garcia-Ribas G, et al. Sci Rep. 10(1):2138. 2020.
2. Safieh M, Korczyn AD, Michaelson DM. BMC Med. 17(1):64. 2019.
3. Calero O, García-Albert L, Rodríguez-Martín A, et al. Sci Rep. 8(1):5969. 2018.
4. Kotredes KP, Oblak A, Pandey RS, et al. Front Aging Neurosci. 13:735524. 2021.
5. Qi G, Mi Y, Shi X, et al. Cell Rep. 34(1):108572. 2021.
6. Lennol MP, Sánchez-Domínguez I, Cuchillo-Ibañez I, et al. Alzheimers Res Ther. 14(1):161. 2022.
7. Sepulveda J, Luo N, Nelson M, et al. J Neurochem. 163(3):247-259. 2022.
8. Foley KE, Hewes AA, Garceau DT, et al. Front Aging Neurosci. 14:838436. 2022.
9. Zhang M, Gong W, Zhang D, et al. Cell Death Dis. 13(4):406. 2022.